Can PPARgamma agonists have a role in the management of obesity-related hypertension? (Q36483455)

14 August 2017

1 reference

title

Can PPARgamma agonists have a role in the management of obesity-related hypertension? (English)

1 reference

14 August 2017

0 references

2

Arya M Sharma

1 reference

14 August 2017

Vasudhevan T Chetty

1

1 reference

14 August 2017

publication date

19 May 2006

1 reference

14 August 2017

published in

Vascular Pharmacology

1 reference

14 August 2017

volume

45

1 reference

14 August 2017

issue

1

1 reference

14 August 2017

page(s)

46-53

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

14 August 2017

1 reference

Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Rosiglitazone reduces urinary albumin excretion in type II diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Hypertension, diabetes mellitus, hypercholesterolemia, and endothelin B receptor-mediated renal nitric oxide release.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Poor glycemic control induces hypertension in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Peroxisome proliferator-activated receptors: nuclear control of metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Insulin resistance in essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Renal protective effect of troglitazone in Wistar fatty rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

The kidney, hypertension, and obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Hypoadiponectinemia is an independent risk factor for hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Evidence against a role of insulin in hypertension in spontaneously hypertensive rats. CS-045 does not lower blood pressure despite improvement of insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Pioglitazone attenuates diet-induced hypertension in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Effects of a low-energy diet and an insulin-sensitizing agent on ambulatory blood pressure in overweight hypertensive patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Salt-regulating hormones in young normotensive obese subjects. Effects of saline load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Adiponectin: action, regulation and association to insulin sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Increased renal medullary oxidative stress produces hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Endothelial dysfunction and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Hyperinsulinemia. A link between hypertension obesity and glucose intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Decrease in renal medullary endothelial nitric oxide synthase of fructose-fed, salt-sensitive hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Interaction of O(2)(-) and NO in the thick ascending limb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Impact of waist circumference on the relationship between blood pressure and insulin: the Quebec Health Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Ion transport across plasma membrane in primary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Association of albuminuria and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Hyperinsulinaemia is not linked with blood pressure elevation in patients with insulinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Peroxisome proliterator-activated receptors, orphans with ligands and functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Mechanism of action of fibrates on lipid and lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Rosiglitazone increases extravasation of macromolecules and endothelial nitric oxide synthase in skeletal muscles of the fructose-fed rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Studies of the mechanisms underlying impairment of beta-adrenoceptor-mediated effects in human hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Vascular protective effects by activation of nuclear receptor PPARgamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Body Mass Index and Total and Cardiovascular Mortality in Men With a History of Cardiovascular Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Glucose-induced vascular smooth muscle dysfunction: the role of protein kinase C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Antihypertensive effects of CS-045 treatment in obese Zucker rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

Effects of pioglitazone on calcium channels in vascular smooth muscle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.11.010

10.1016/J.VPH.2005.11.010

7 January 2021

Identifiers

DOI

1 reference

14 August 2017

1 reference